Bio Path Story

<div class='circular--portrait' style='background:#3b5998;color: #F0F8FF;font-size:4em;'>BP</div>
BPTH -- USA Stock  

USD 3.47  0.09  2.53%

It seems as Bio Path will continue to recover much faster as its share price surged up 30.30% today. The company's current daily volatility is 5.98 percent, with a beta of -0.15 and an alpha of -0.52 over DOW. As many investors are getting excited about pharmaceutical products, it is fair to concentrate on Bio Path Holdings. We will evaluate why recent Bio Path price moves suggest a bounce in September.
Published over three months ago
View all stories for Bio Path | View All Stories
Should you take over Bio Path Holdings after the current volatility rise?
Bio Path Holdings currently holds about 14.41 M in cash with (10.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.9. We provide trade advice to complement the prevailing expert consensus on Bio Path Holdings. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Investing in Bio Path, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Bio Path along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Bio Path's Liquidity

Bio Path financial leverage refers to using borrowed capital as a funding source to finance Bio Path Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bio Path financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Bio Path's total debt and its cash.

How Bio Path utilizes its cash?

To perform a cash flow analysis of Bio Path, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bio Path is receiving and how much cash it distributes out in a given period. The Bio Path cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Bio Path Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (8.36 Million)

Bio Path Correlation with Peers

Investors in Bio Path can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Bio Path Holdings. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Bio Path and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Bio Path is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Bio Path for more details

Acquisition by Amy Sing of 25000 shares of Bio Path subject to Rule 16b-3

Legal trades by Bio Path insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bio Path insider trading alert for grant of common stock option (right to buy) by Amy Sing, the corporate stakeholder, on 23rd of August 2020. This event was filed by Biopath Holdings Inc with SEC on 2016-04-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Going after Bio Path Financials

We consider Bio Path moderately volatile. Bio Path Holdings secures Sharpe Ratio (or Efficiency) of 0.0113, which signifies that the company had 0.0113% of return per unit of risk over the last month. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-seven technical indicators for Bio Path Holdings, which you can use to evaluate future volatility of the firm. Please confirm Bio Path Holdings risk adjusted performance of (0.16), and Mean Deviation of 2.87 to double-check if the risk estimate we provide is consistent with the expected return of 0.0679%.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Our perspective of the current Bio Path rise

Kurtosis is down to 6.38. It may hint to a possible volatility drop. As of the 22nd of August, Bio Path shows the risk adjusted performance of (0.16), and Mean Deviation of 2.87. Bio Path Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Bio Path Holdings, which can be compared to its rivals. Please confirm Bio Path Holdings coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Bio Path Holdings is priced correctly, providing market reflects its regular price of 5.16 per share. Given that Bio Path has jensen alpha of (0.52), we suggest you to validate Bio Path Holdings's prevailing market performance to make sure the company can sustain itself at a future point.

The Bottom Line

While some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Bio Path may offer a potential longer-term growth to stockholders. To summarize, as of the 22nd of August 2020, our final 30 days buy-or-sell advice on the company is Cautious Hold. We believe Bio Path is currently undervalued with very low probability of bankruptcy for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Bio Path Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com